EU Wellness Assessment Software: Where Is the Medical-Device Boundary?

Short answer: In the EU, a wellness-assessment app is not automatically medical-device software merely because it collects personal measurements or displays a score. The manufacturer’s intended purpose and the functions that transform data matter. The Medical Device Coordination Group’s June 2025 revision of its software guidance distinguishes non-medical wellness and fitness applications from software intended for a medical purpose. A buyer should review the actual claims, outputs and connected equipment before deciding which regulatory route to investigate. A word such as “wellness” on a sales page is not a reliable substitute for that review.

What changed in the guidance?

The Commission’s guidance index lists MDCG 2019-11 rev.1, Guidance on Qualification and Classification of Software, as published in June 2025. The document says the revision clarifies intended purpose, Annex XVI software and modular products, and adds examples. It applies its qualification logic to apps whether they run on a phone, in the cloud or on another platform. It is guidance on interpreting the Medical Devices Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR), not a new approval for a particular assessment system. The index expressly says MDCG guidance is not legally binding.

The document explains that medical-device software has an intended purpose within the medical-device or IVD definitions. Its discussion of qualification says that software solely intended for non-medical uses, including wellness or fitness apps, does not qualify as medical-device software, while software processing or interpreting information for a medical intended purpose may do so. A diagnostic or treatment-related output deserves different scrutiny from a general lifestyle dashboard. Importantly, risk of harm alone does not establish whether software is a medical device; qualification begins with the defined purpose and function. The guidance also identifies special cases involving software that drives or influences a regulated device or falls under the MDR’s Annex XVI framework for certain products without a medical purpose.

Questions for an assessment buyer

Request a written intended-purpose statement for the exact software version and each optional module. Compare it with the website, sales presentation, in-app labels, report headings and staff scripts. Ask whether the system merely stores or displays information, calculates general wellness trends, or produces patient-specific findings used for diagnosis, treatment or monitoring. Ask which data are inputs, how outputs are presented, who is expected to act on them and whether the software controls another device. These questions follow the guidance’s decision steps; they do not classify a TUOKE product.

A useful purchase file would map each function to its claim and intended user. It should identify the legal manufacturer, the software release, connected hardware, change-control process and the documents supporting any proposed medical purpose. If the supplier says a medical-device route applies, request the relevant conformity documentation and an explanation of the classification rather than assuming every health-related app receives the same class. The guidance’s Rule 11 discussion shows that software used for diagnostic or therapeutic decisions can be classified differently according to the significance and potential impact of the information. The precise answer depends on the real function and context of use.

Modularity matters. The 2025 revision discusses platforms containing both medical and non-medical modules and says manufacturers should delineate boundaries, dependencies and interfaces. A simple booking or record-storage feature does not become diagnostic just by sharing an interface with an assessment function. Equally, putting a decision-support function inside a larger wellness platform does not make its medical purpose disappear. A buyer should ask whether a feature upgrade changes outputs or claims, who validates that change and which parts of the combined system are covered by any conformity assessment.

Limits and practical next step

This is EU guidance, not a product-specific legal determination or medical advice. The 2025 revision is background for a current procurement decision, not breaking news. The cited sources do not establish that any TUOKE wellness-assessment product is a medical device, CE-marked, diagnostically accurate or cleared to make a clinical claim. Local implementation, other applicable EU rules and the complete product documentation may affect the answer. For a proposed EU launch, obtain a qualified regulatory review of the exact version, claims and configuration before making medical statements or relying on a supplier’s generic certificate.

Use the TUOKE wellness-assessment category as a starting point for model-specific questions, not as evidence of regulatory status. Preserve the final intended-purpose statement alongside the purchase documents so later software updates and marketing edits can be checked against it.

Sources

• European Commission, MDCG endorsed guidance index, lists MDCG 2019-11 rev.1 as June 2025; reviewed 15 October 2026.
• Medical Device Coordination Group, MDCG 2019-11 rev.1, Guidance on Qualification and Classification of Software, June 2025 revision; reviewed 15 October 2026.